menu
    • menu
    [{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series C Financing","leadProduct":"AT-100","moa":"IL-8","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Airway Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Airway Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AT-100","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Airway Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Celonic","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"AT-100","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Airway Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Airway Therapeutics \/ Airway Therapeutics"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"rhSP-D","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intratracheal","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"rhSP-D","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intratracheal","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"rhSP-D","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Zelpultide Alfa","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Zelpultide Alfa","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Zelpultide Alfa","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Airway Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Zelpultide Alfa","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Airway Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Airway Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Airway Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Airway Therapeutics

    Menu

    Airway Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelpultide Alfa

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airway Therapeutics Starts Phase 3 Zelpultide Alfa Trial for Neonates

                            Details : AT-100 (zelpultide alfa) is a recombinant version of human surfactant protein D (rhSP-D), being developed foe the treatment of bronchopulmonary dysplasia.

                            Brand Name : AT-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 15, 2024

                            Lead Product(s) : Zelpultide Alfa

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelpultide Alfa

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infant...

                            Details : AT-100 (zelpultide alfa) is a recombinant version of the endogenous human SP-D, a protein essential to the lung’s immune defense in reducing inflammation and infection while modulating immune responses for the patients of Bronchopulmonary Dysplasia.

                            Brand Name : AT-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : Zelpultide Alfa

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelpultide Alfa

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm I...

                            Details : AT-100 (zelpultide alfa) is a recombinant version of the endogenous human SP-D, a protein essential to the lung’s immune defense in reducing inflammation and infection while modulating immune response. It is being investigated in preterm infants for br...

                            Brand Name : AT-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 11, 2023

                            Lead Product(s) : Zelpultide Alfa

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelpultide Alfa

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airway Therapeutics Opens International Clinical Trial Sites and Treats First Patient in Spain in Phase 1b Stu...

                            Details : Zelpultide alfa (AT-100) is a novel recombinant version of the endogenous human protein hSP-D, a protein that reduces inflammation and infection in the body while modulating the immune response to break the cycle of injury and inflammation.

                            Brand Name : AT-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 03, 2022

                            Lead Product(s) : Zelpultide Alfa

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhSP-D

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for B...

                            Details : In preclinical studies, AT-100 has shown to reduce inflammation and infection triggered by mechanical ventilation and oxygen support, and ultimately reduce the onset of lung damage.

                            Brand Name : AT-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 31, 2022

                            Lead Product(s) : rhSP-D

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhSP-D

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airway Therapeutics Announces FDA Acceptance of Ind for AT-100’s Second Indication IN Severe Covid-19 Patien...

                            Details : Preclinical studies have shown that the human recombinant protein ,AT-100, can safely minimise inflammation and infection while modulating the immune response in a variety of respiratory diseases both inside and outside the lung.

                            Brand Name : AT-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 12, 2021

                            Lead Product(s) : rhSP-D

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhSP-D

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airway Therapeutics Announces FDA Acceptance of Ind for At-100 IN Preterm Infants at Risk for Bronchopulmonary...

                            Details : AT-100 is a novel human recombinant protein that has been shown in preclinical studies to reduce inflammation and infection triggered in very preterm babies by mechanical ventilation and oxygen support and ultimately reduce the onset of lung damage.

                            Brand Name : AT-100

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 26, 2021

                            Lead Product(s) : rhSP-D

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : IND Enabling

                            Recipient : Celonic

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Airway Therapeutics and Celonic Group Collaborate to Produce AT-100 as Promising New Candidate for Coronavirus

                            Details : Based on the agreement, Celonic will be responsible for process optimization and GMP manufacturing of AT-100 for clinical study.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 20, 2020

                            Lead Product(s) : AT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : IND Enabling

                            Recipient : Celonic

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-100

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus

                            Details : Airway is aiming to enter the clinic later this year with AT-100 as an investigational preventive treatment for the serious respiratory disease.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 11, 2020

                            Lead Product(s) : AT-100

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Airway Therapeutics

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $15.5 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Airway Therapeutics Closes $15.5 Million Series C Financing to Advance Preclinical and Clinical Research and D...

                            Details : This funding will enable clinical development of AT-100 (rhSP-D), while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 08, 2020

                            Lead Product(s) : AT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $15.5 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth